PDS Biotechnology (NASDAQ: PDSB) shares press release on clinical and Q2 results

Rhea-AI Filing Summary

PDS Biotechnology Corporation filed a current report stating that it issued a press release on August 13, 2025 providing an update on its clinical programs and financial results for the quarter ended June 30, 2025. The report explains that the press release is attached as Exhibit 99.1 and is being treated as information that is furnished rather than filed under securities law, which affects the level of legal liability associated with it. The filing itself does not detail the results or clinical data, but directs readers to the attached press release for those specifics.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false000147209100014720912025-08-132025-08-13

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 13, 2025

PDS BIOTECHNOLOGY CORPORATION

(Exact Name of Registrant as Specified in Charter)

Delaware	001-37568	26-4231384
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

303A College Road East, Princeton, NJ 08540

(Address of Principal Executive Offices, and Zip Code)

(800) 208-3343

Registrant’s Telephone Number, Including Area Code

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐
Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.00033 per share	PDSB	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Yes ☐ No ☐

Item 2.02 Results of Operation and Financial Condition.

On August 13, 2025, PDS Biotechnology Corporation (the “Company”) issued a press release announcing an update to its clinical programs and its financial results for the quarter ended June 30, 2025. The Company is furnishing a copy of the press release, which is attached hereto as Exhibit 99.1.

In accordance with General Instruction B.2 of Form 8-K, the information set forth in this Current Report on Form 8-K (including Exhibit 99.1) is deemed to be “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of the section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number		Description
99.1		Press Release dated August 13, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		PDS BIOTECHNOLOGY CORPORATION
Date: August 13, 2025		By:	/s/ Frank Bedu-Addo, Ph.D.
		Name: Frank Bedu-Addo, Ph.D.
		Title: President and Chief Executive Officer

FAQ

What did PDSB disclose in this 8-K filing?

PDS Biotechnology Corporation disclosed that it issued a press release on August 13, 2025 providing an update on its clinical programs and financial results for the quarter ended June 30, 2025, which is attached as Exhibit 99.1.

Does this PDSB 8-K include detailed financial results for the quarter ended June 30, 2025?

The 8-K notes that financial results for the quarter ended June 30, 2025 are discussed in the attached press release (Exhibit 99.1), but the specific numbers are not included in the body of this report.

How is the PDSB press release treated under securities law in this filing?

The company states that the information in the report, including Exhibit 99.1, is deemed to be "furnished" and not "filed" under the Securities Exchange Act of 1934, which limits the liabilities associated with this information.

What exhibit is attached to this PDSB 8-K?

Exhibit 99.1 is a press release dated August 13, 2025, and Exhibit 104 is the cover page interactive data file embedded within the Inline XBRL document.

Who signed the PDSB 8-K report dated August 13, 2025?

The report was signed on behalf of PDS Biotechnology Corporation by Frank Bedu-Addo, Ph.D., who is the President and Chief Executive Officer.